Related Experiment Videos
Postinfarction metoprolol treatment: effects on prognosis in relation to serum cholesterol concentrations
1Department of Medicine, Karolinska Institutet, Danderyd Hospital, Sweden.
Insights
Metoprolol use after myocardial infarction reduced reinfarctions in patients with lower cholesterol and mortality in those with higher cholesterol. These benefits of beta-blockade were observed regardless of serum cholesterol levels.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockade is a standard treatment for patients post-myocardial infarction.
- The influence of serum cholesterol on the efficacy of beta-blockers like metoprolol requires further elucidation.
Purpose of the Study:
- To evaluate the impact of metoprolol on cardiovascular outcomes in post-myocardial infarction patients stratified by serum cholesterol concentrations.
- To determine if the benefits of metoprolol are dependent on baseline or achieved cholesterol levels.
Main Methods:
- A double-blind, randomized, placebo-controlled study.
- 154 patients received metoprolol (100 mg twice daily), and 147 received placebo.
- Follow-up was conducted over 3 years, with serum cholesterol levels monitored.
Main Results:
- Metoprolol did not significantly alter total serum cholesterol concentrations.
- In patients with cholesterol ≤ 6.7 mmol/l, metoprolol reduced nonfatal reinfarctions (7% vs. 24%, p < 0.01).
- In patients with cholesterol > 6.7 mmol/l, metoprolol lowered mortality (8% vs. 20%, p < 0.05).
Conclusions:
- The cardioprotective effects of metoprolol following myocardial infarction are evident across different serum cholesterol levels.
- Conventional beta-blockade therapy with metoprolol provides significant benefits independent of cholesterol concentration.
Abstract:
In a double-blind randomized study of 154 postmyocardial infarction patients assigned to metoprolol (100 mg twice daily) and 147 patients assigned placebo, the outcome during a 3-year follow-up according to serum cholesterol concentrations was evaluated. There was no indication that metoprolol influenced the total serum cholesterol concentration. The median cholesterol value at 3 months was 6.7 mmol/l. In patients with cholesterol less than or equal to 6.7 mmol/l, nonfatal reinfarctions were reduced in the metoprolol group (7 vs. 24%; p less than 0.01). In patients with cholesterol greater than 6.7 mmol/l, mortality was lower in those treated with metoprolol (8 vs. 20%; p less than 0.05). The beneficial effect of conventional postinfarction beta-blockade with metoprolol is independent of serum cholesterol concentration.